Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines
(1993; 94 pages)
Table des matières
Afficher le documentFOREWORD
Ouvrir ce répertoire et afficher son contenu1. INTRODUCTION
Ouvrir ce répertoire et afficher son contenu2. GENERAL CONSIDERATIONS IN HERBAL MEDICINE RESEARCH
Fermer ce répertoire3. RESEARCH STUDIES
Afficher le documentLITERATURE BACKGROUND
Afficher le documentPROTOCOL PREPARATION
Afficher le documentQUALITY SPECIFICATIONS OF PLANT MATERIALS AND PREPARATION
Ouvrir ce répertoire et afficher son contenuNON-CLINICAL STUDIES
Fermer ce répertoireCLINICAL TRIALS USING HERBAL MEDICINES
Afficher le documentCLINICAL TRIAL PROTOCOL DEVELOPMENT
Afficher le documentPHASES OF A CLINICAL TRIAL
Afficher le documentETHICS REVIEW BOARD
Afficher le documentRESPONSIBILITIES OF INVESTIGATORS
Afficher le documentRESPONSIBILITIES OF THE SPONSOR
Afficher le documentDATA MANAGEMENT
Afficher le documentSTATISTICAL ANALYSIS
Afficher le documentREPORTING
Afficher le documentEVALUATION OF HERBAL MEDICINE RESEARCH
Ouvrir ce répertoire et afficher son contenuTECHNOLOGY TRANSFER AND EDUCATION
Ouvrir ce répertoire et afficher son contenu4. USING THE GUIDELINES
Ouvrir ce répertoire et afficher son contenuANNEXES
Afficher le documentNOTES
Afficher le documentBIBLIOGRAPHY
Afficher le documentSELECTED WHO PUBLICATIONS OF RELATED INTEREST
 

ETHICS REVIEW BOARD

The trial protocol should be considered by an ethics review board. The board will generally be established at an institutional level but boards existing at a regional or national level can also be used. The board will be an independent body constituted of both medical and non-medical members who are not involved in the experimental activity of the trial under review. The board will verify that the rights of the patients participating in the trial are protected and that the trial is justified in medical and social terms. The board will also consider the suitability of the trial protocol, patient selection and patient protection, and issues of informed consent of patients. The work of the board should be guided by the World Medical Association’s Declaration of Helsinki (Annex 2).

The board will work under standard operating procedures which will be developed by each institution taking into consideration all necessary requirements of local regulatory authorities and related governmental agencies including such rules as those for Good Clinical Practice (GCP).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013